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BACKGROUND: In ST- segment– elevation myocardial infarction, angiography- based complete revascularization is superior 
to culprit- lesion- only percutaneous coronary intervention. Quantitative flow ratio (QFR) is a novel, noninvasive, vasodilator- 
free method used to assess the hemodynamic significance of coronary stenoses. We aimed to investigate the incremental 
value of QFR over angiography in nonculprit lesions in patients with ST- segment– elevation myocardial infarction undergoing 
angiography- guided complete revascularization.
METHODS AND RESULTS: This was a retrospective post hoc QFR analysis of untreated nontarget vessels (any degree of diam-
eter stenosis [DS]) from the randomized multicenter COMFORTABLE AMI (Comparison of Biolimus Eluted From an Erodible 
Stent Coating With Bare Metal Stents in Acute ST- Elevation Myocardial Infarction) trial by assessors blinded for clinical 
outcomes. The primary end point was cardiac death, spontaneous nontarget vessel myocardial infarction, and clinically 
indicated nontarget vessel revascularization (ie, ≥70% DS by 2- dimensional quantitative coronary angiography or ≥50% DS 
and ischemia) at 5 years. Of 1161 patients with ST- segment– elevation myocardial infarction, 946 vessels in 617 patients 
were analyzable by QFR. At 5 years, the rate of the primary end point was significantly higher in patients with QFR ≤0.80 
(n=35 patients, n=36 vessels) versus QFR >0.80 (n=582 patients, n=910 vessels) (62.9% versus 12.5%, respectively; haz-
ard ratio [HR], 7.33 [95% CI, 4.54– 11.83], P<0.001), driven by higher rates of nontarget vessel myocardial infarction (12.8% 
versus 3.1%, respectively; HR, 4.38 [95% CI, 1.47– 13.02], P=0.008) and nontarget vessel revascularization (58.6% versus 
7.7%, respectively; HR, 10.99 [95% CI, 6.39– 18.91], P<0.001) with no significant differences for cardiac death. Multivariable 
analysis identified QFR ≤0.80 but not ≥50% DS by 3- dimensional quantitative coronary angiography as an independent 
predictor of the primary end point. Results were consistent, including only >30% DS by 3- dimensional quantitative coronary 
angiography.
CONCLUSIONS: Our study suggests incremental value of QFR over angiography- guided percutaneous coronary intervention 
for nonculprit lesions among patients with ST- segment– elevation myocardial infarction undergoing primary percutaneous 
coronary intervention.
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The prevalence of multivessel disease in patients with ST- segment– elevation myocardial infarc-tion (STEMI) amounts to ≈50%.1 These patients 
are at highest risk for future cardiac events2,3 includ-
ing an increased risk of mortality, and several trials 
have investigated the role of complete versus culprit- 
lesion- only revascularization to further improve out-
comes.4– 11 Recently, outcome data of the COMPLETE 
(Complete Versus Culprit- Only Revascularization 
Strategies to Treat Multivessel Disease After Early PCI 
for STEMI) trial showed a reduction in cardiovascular 
death and myocardial infarction (MI) in favor of pa-
tients undergoing complete angiography- guided per-
cutaneous coronary intervention (PCI).12
Hemodynamic lesion assessment with use of frac-
tional flow reserve (FFR) assumes a class IA indication 
in guidelines on myocardial revascularization among 
patients with chronic coronary syndromes13 considered 
for PCI.14 Although 2 randomized clinical trials (RCTs) 
reported improved outcomes of FFR- guided complete 
revascularization versus culprit- lesion- only PCI in pa-
tients with acute MI,7,8 the superiority of the FFR- guided 
strategy was driven by a reduction in repeat revascular-
ization and a direct comparison of angiography- guided 
versus FFR- guided complete revascularization in this 
patient population is missing to date. The ongoing 
FLOWER- MI (Flow Evaluation to Guide Revascularization 
in Multivessel ST- Elevation Myocardial Infarction) trial is 
currently investigating the issue (NCT02943954).
From a practical standpoint, the use of invasive FFR 
in the acute setting of STEMI is inconvenient because 
of the need for additional nonculprit vessel wire manip-
ulation, the administration of adenosine with potential 
adverse effects, lengthening of procedure time, and 
additional costs.15,16
Quantitative flow ratio (QFR) has emerged as a novel, 
noninvasive, vasodilator- free method to calculate FFR 
from biplane angiography using computational mod-
eling of 3- dimensional (3D) quantitative coronary angi-
ography (QCA) and TIMI (Thrombolysis in Myocardial 
Infarction) frame counts.17– 19 It has been broadly vali-
dated against FFR in chronic coronary syndromes19 and 
more recently for the assessment of nonculprit lesion 
(NCL) in STEMI, showing areas under the curve (AUCs) 
of 0.89 to 0.9720– 23 with good agreement between QFR 
assessment at the time of the index and subsequent 
staged procedure.20,22 QFR is time efficient and omits 
any additional invasive procedures, drug administra-
tion, or further costs18; therefore, it is potentially use-
ful in patients with STEMI. In the COMFORTABLE AMI 
(Comparison of Biolimus Eluted From an Erodible Stent 
Coating With Bare Metal Stents in Acute ST- Elevation 
Myocardial Infarction) trial, an international multicenter 
RCT of patients with STEMI to compare bare metal 
stents with biolimus- eluting stents, patients underwent 
angiography- guided complete revascularization for ste-
noses ≥70% by visual estimate.24 We aimed to inves-
tigate the incremental value of nontarget vessel QFR 
over angiography- guided PCI to predict major adverse 
cardiac events during follow- up throughout 5 years.
METHODS
The data that support the findings of this study are 




• Quantitative flow ratio is a novel, noninvasive, 
vasodilator- free method to assess the hemody-
namic significance of coronary stenoses.
• In patients with ST- segment– elevation myocar-
dial infarction undergoing angiography- guided 
complete revascularization of all nonculprit le-
sions with ≥70% stenosis by visual estimate, 
quantitative flow ratio identified additional le-
sions at risk for future nontarget vessel– related 
events through 5 years of follow- up.
What Are the Clinical Implications?
• Quantitative flow ratio showed incremental 
value over angiography alone in nonculprit le-
sion assessment in patients with ST- segment– 
elevation myocardial infarction.
• Quantitative flow ratio may emerge as a con-
venient, noninvasive, vasodilator- free method 
to assess nonculprit lesion significance in pa-
tients with ST- segment– elevation myocardial 
infarction.
Nonstandard Abbreviations and Acronyms
2D 2- dimensional
3D 3- dimensional
%DS percent diameter stenosis
DS diameter stenosis
FFR fractional flow reserve
NCL nonculprit lesion
non– TV- MI nontarget vessel myocardial 
infarction
non- TVR nontarget vessel revascularization
MI SYNTAX Myocardial Infarction TAXus and 
Cardiac Surgery
QFR quantitative flow ratio
TV- MI target vessel myocardial infarction
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Study Population
All untreated nontarget vessels from the 
COMFORORTABLE AMI cohort,24 at any degree of 
stenosis, were eligible for QFR measurement after 
angiography- guided complete revascularization. 
The study design as well as 1- , 2- , and 5- year out-
comes have been previously published.24– 27 Briefly, 
COMFORTABLE AMI was a single- blinded RCT of 
1161 patients with STEMI undergoing primary PCI 
comparing bare metal stents and biolimus- eluting 
stents at 11 sites in Europe and Israel between 2009 
and 2011. The main exclusion criteria were MI sec-
ondary to stent thrombosis; mechanical complica-
tions of acute MI; noncardiac comorbid conditions 
with life expectancy <1 year; planned surgery within 
6 months of PCI (unless dual antiplatelet therapy was 
maintained throughout the perisurgical period); his-
tory of bleeding diathesis or known coagulopathy; 
use of vitamin K antagonists; known intolerance to 
aspirin, clopidogrel, heparin, stainless steel, bioli-
mus, or contrast material; and (possible) pregnancy. 
Patients were 1:1 randomly assigned to receive ei-
ther bare metal stents or biolimus- eluting stents. 
The study complied with the Declaration of Helsinki 
and was approved by all institutional ethics commit-
tees. All patients provided written informed consent. 
Clinical end points were adjudicated by an independ-
ent clinical events committee.
Angiography
All patients underwent diagnostic angiography using 
standard angiographic projections with at least 2 or-
thogonal planes per region of interest at the time of 
PCI. Administration of nitroglycerin before angiography 
was performed whenever clinically feasible. Complete 
revascularization based on visual estimation from angi-
ography (ie, stenosis ≥70% by visual estimate) was rec-
ommended with staged PCI to be performed within no 
longer than 3 months. Treatment of lesions between 
50% and 70% were left to the discretion of the opera-
tors. All untreated vessels at any degree of stenosis un-
derwent QFR if the quality was sufficient (see below). 
Untreated lesions were categorized in focal ≤20 mm 
versus diffuse >20 mm.28
QFR Analysis
QFR analysis was performed in the Bern University 
Hospital Corelab by certified analysts blinded for pa-
tient outcomes using dedicated software (QAngio 
XA 3D version 1.2, Medis Medical Imaging Systems) 
(Figure  1). If obtained, optimal angiographic projec-
tions for QFR computation as defined by the software 
manufacturers were used. Contrast QFR using frame 
counting16 was measured from the ostium of the index 
vessel to a distal anatomic landmark visible on both 
projections at a vessel diameter of ≥2.0 mm. Distal end 
point selection at a minimum vessel diameter of ≥1.5 
Figure 1. Quantitative flow ratio (QFR) analysis.
Example of a left anterior descending artery requiring revascularization according to a QFR value of 0.76 
that was missed by angiography. A and B, Two angiographic projections ≥25° apart, (C) 3- dimensional 
vessel reconstruction, (D) vessel diameter, and QFR curves over the length of the vessel.
A B
C D
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was chosen in vessels with ≤2.5 to 2.0 mm proximal 
reference diameter, which is in line with a previous 
study.20 All analyses were performed according to a 
previously suggested standard operating procedure.18 
The conventional cutoff of ≤0.80 for detection of sig-
nificant ischemia was used.16– 18 All nontarget vessels 
including major side branches (obtuse marginal, inter-
mediate branch, diagonal branch) without staged PCI 
and ≥2.0 mm proximal reference diameter were eligible 
for QFR analysis. The exclusion criteria for QFR analy-
sis were absence of 2 projections with an angle ≥25° 
apart; lack of isocenter calibration; substantial vessel 
overlap or vessel foreshortening; severe tortuosity; 
poor contrast; TIMI flow ≤2; tachycardia >100 per min-
ute; atrial or ventricular arrhythmia; ostial left main or 
ostial right coronary artery stenosis; bifurcation lesions 
with 1,1,1 Medina classification; vessels with retrograde 
fillings; grafted coronary arteries; and bypass grafts.
Intraobserver and Interobserver Reliability
For intraobserver and interobserver reliability testing, re-
peated QFR analyses by 3 independent Corelab ana-
lysts including 20 randomly assigned vessels were used.
Clinical End Points
The primary end point was the composite of car-
diac death, spontaneous nontarget vessel MI (non– 
TV- MI), and clinically indicated nontarget vessel 
revascularization (non- TVR) throughout 5  years in 
patients with at least 1 vessel with QFR ≤0.80 versus 
patients with all vessels with QFR >0.80. Secondary 
end points included the individual components of 
the primary end point, any spontaneous MI, and any 
revascularization.
Detailed definitions of all clinical end points were 
previously reported.24
Cardiac death was defined as any death from im-
mediate cardiac cause (eg, MI, low- output failure, fatal 
arrhythmia), unwitnessed death and death of unknown 
cause, and all procedure- related deaths, including 
those related to concomitant treatment.
MI was defined according to the extended histori-
cal definition.29 All MIs (TV- MI, non– TV- MI, Q- wave MI, 
non– Q- wave MI) were spontaneous MIs >48  hours 
after intervention. Periprocedural MIs ≤48 hours after 
intervention were excluded from the present analysis. 
TV- MI was defined as MI attributed to the vessel inter-
vened at baseline and non– TV- MI as MI attributed to a 
vessel not intervened at baseline.
Non- TVR was clinically indicated using the same defi-
nition as for target vessel revascularization, ie, lesions 
with diameter stenosis (DS) ≥70% (by 2- dimensional 
[2D] QCA) or DS ≥50% (by 2D QCA) and 1 of the fol-
lowing: (1) a positive history of recurrent angina pec-
toris presumably related to the nontarget vessel; (2) 
objective signs of ischemia at rest (ECG changes) or 
during exercise test (or equivalent) presumably related 
to the nontarget vessel; and (3) abnormal results of any 
invasive functional diagnostic test (eg, Doppler flow ve-
locity reserve and FFR).24
We performed multivariable predictor analysis of 
the primary end point and determined the predictive 
power of QFR ≤0.80 (accuracy, sensitivity, specific-
ity, positive predictive value [PPV], negative predictive 
value [NPV]) to detect the primary end point.
Statistical Analysis
Continuous variables are presented as mean±SD 
and categorical variables as counts with percent-
ages. Baseline, procedural, and 3D QCA variables 
were compared using chi- square test, Fisher exact 
test, or t test, as appropriate. Cumulative incidences 
of the clinical end points through 5 years and from 
1 to 5 years were compared using Cox proportional 
hazard models and are displayed via Kaplan- Meier 
curves. Hazard ratios (HRs) are provided with 95% 
confidence intervals (CIs). To identify predictors of 
the 5- year primary end point, we ran univariable Cox 
proportional hazards models for all patient baseline 
characteristics, QFR ≤0.80, and DS ≥50%, and we 
subsequently ran a multivariable Cox proportional 
hazards model including all variables that had a sig-
nificant association with the primary end point in uni-
variable analysis. We conducted receiver operating 
characteristic (ROC) analysis to assess the sensitiv-
ity, specificity, and PPV/NPV of QFR ≤0.80 for the 
5- year primary end point. To account for changing 
event risk over time, we additionally performed cu-
mulative case/dynamic control (ie, time- dependent) 
ROC analyses at 1, 2, 3, 4, and 5  years using the 
Kaplan- Meier estimator of the censoring distribution. 
All analyses were conducted in Stata 15 and RStudio 
1.1.463. Significance tests were 2- tailed with a sig-
nificance level set to 0.05.
RESULTS
Baseline Patient and Procedural 
Characteristics
A total of 1161 patients with STEMI were randomized 
and 1157 patients included in the present analysis. At 
5  years, clinical follow- up information was available 
in 1100 patients, of whom 927 (84.3%) patients were 
eligible for QFR analysis. After exclusion attributable 
to clinical or technical exclusion criteria as shown in 
Figure 2, a total of 617 (56.1%) patients with 946 ves-
sels were available for the final analysis. Baseline clini-
cal and procedural characteristics were similar for the 
QFR ≤0.80 group and QFR >0.80 group, except for 
MI SYNTAX (Myocardial Infarction TAXus and Cardiac 
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Surgery) score (ie, post– wire- crossing SYNTAX 
score),30,31 which was significantly higher, and DS 
≥50% by 3D QCA, which was significantly more fre-
quent in the QFR ≤0.80 group (Table 1).
Three- Dimensional QCA and QFR 
Characteristics
Mean (percent DS [DS%]) of NCL was 36.5% (±10.5, 
range 9.5%– 70.3%) (Figure S1). Only 1 of 946 (0.1%) 
vessels revealed DS% above the revascularization 
threshold of ≥70% (DS 70.3%). The mean QFR of 
NCL was 0.93 (±0.09, range 0.21– 1.00) (Figure S2). In 
36 of 946 (3.8%) vessels QFR was ≤0.80 and in 910 
(96.2%) QFR was >0.80. In the QFR ≤0.80 group, left 
anterior descending artery was the most frequent 
vessel (77.8%) followed by the right coronary artery 
(19.4%) and the left circumflex artery (2.8%). The ma-
jority (66.7%, n=24) of vessels with QFR ≤0.80 exhib-
ited diffuse disease (ie, lesion length >20 mm28). Most 
mismatches between angiographic and functional le-
sion severity (QFR ≤0.80 but DS <50%) were located 
in the left anterior descending (83.3%) artery, fewer in 
the right coronary artery (16.7%), and none in the left 
circumflex artery (Figure  3). QCA analyses indicated 
that DS% (P<0.001) and area stenosis (P<0.001) were 
higher, minimal lumen diameter (P<0.001) was lower, 
and lesion length (P<0.001) was longer in vessels with 
QFR ≤0.80 versus >0.80 (Table 2).
Intraobserver and Interobserver 
Reliability
Intraobserver reliability analysis showed agreement on 
QFR classification (QFR ≤0.80 versus >0.80) in 100% 
of vessels. Intraclass correlation coefficient for con-
tinuous QFR was 0.67. Interobserver reliability analy-
sis showed agreement on QFR classification in 90% 
of vessels, an intraclass correlation coefficient of 0.76, 
and a κ coefficient of 0.68.
Figure 2. Patient flowchart.
Depicted are numbers of patients (vessels). CTO indicates chronic total occlusion; PCI, percutaneous 
coronary intervention; QFR, quantitative flow ratio; RCA, right coronary artery; STEMI, ST- segment– 
elevation myocardial infarction; and TIMI, thrombolysis in myocardial infarction.
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Clinical Events
Cumulative event rates at 5 years are summarized in 
Table  3 and Figure  4. The proportional hazards as-
sumption was met for all reported outcomes. At 
5 years of follow- up, the rate of the primary end point 
was significantly higher in the QFR ≤0.80 group as 
compared with the QFR >0.80 group (62.9% versus 
12.5%, respectively; HR, 7.33 [95% CI, 4.54– 11.83], 
P<0.001).
This was driven by differences in spontaneous 
non– TV- MI (12.8% versus 3.1%, respectively; HR, 4.38 
[95% CI, 1.47– 13.02], P=0.008) and non- TVR (58.6% 
versus 7.7%, respectively; HR, 10.99 [95% CI, 6.39– 
18.91], P<0.001). The non– TV- MIs occurred after a 
Table 1. Patient and Procedural Characteristics
QFR ≤0.80 (n=35) QFR >0.80 (n=582) P Value
Patient characteristics (patient- level)
Women, n (%) 10 (28.6) 133 (22.9) 0.415
Age, y 63.1±11.4 60.7±11.6 0.232
BMI, kg/m2 27.3±3.5 27.0±4.0 0.730
Diabetes mellitus, n (%) 8 (22.9) 78 (13.4) 0.130
Hypertension, n (%) 22 (62.9) 262 (45.0) 0.054
Hypercholesterolemia, n (%) 25 (71.4) 323 (55.8) 0.080
Family history of CAD, n (%) 13 (38.2) 185 (32.2) 0.457
Killip I or II, n (%) 33 (94.3) 577 (99.1) 0.055
Killip IV, n (%) 1 (2.9) 3 (0.5) 0.209
Left ventricular function, % 49.1±10.4 48.7±10.3 0.840
MI SYNTAX score 16.2±10.9 11.1±7.6 <0.001
Procedural characteristics (patient- level)
Infarct vessel 0.003
LM artery, n (%) 0 (0.0) 1 (0.2)
LAD artery, n (%) 5 (14.3) 251 (43.1)
LCX artery, n (%) 7 (20.0) 80 (13.7)
RCA, n (%) 23 (65.7) 250 (43.0)
Lesions in infarct vessel, n 1.03 (0.17) 1.09 (0.33) 0.236
Type of intervention 0.209
PCI— implantation of stent(s), n (%) 34 (97.1) 579 (99.5)
PCI— only balloon dilatation, n (%) 1 (2.9) 3 (0.5)
Stents per lesion, n 1.37±0.81 1.41±0.72 0.766
Total stent length per lesion, mm 28.4±15.5 26.8±13.4 0.505
Average stent diameter, mm 3.24±0.49 3.20±0.41 0.569
Direct stenting, n (%) 11 (32.4) 175 (30.2) 0.848
Maximal balloon pressure, atm 16.3±3.5 15.3±3.2 0.073
Thrombus aspiration, n (%) 23 (65.7) 353 (60.7) 0.597
Nontarget vessel (patient- level) n=35 n=582 <0.001
LAD artery, n (%) 27 (77.1) 183 (31.4)
LCX artery, n (%) 1 (2.9) 255 (43.8)
RCA, n (%) 7 (20.0) 144 (24.7)
DS ≥50% by 3D QCA, n (%) 23 (65.7) 38 (6.5) <0.001
Nontarget vessel (vessel- level) n=36 n=910 <0.001
LAD artery, n (%) 28 (77.8) 226 (24.8)
LCX artery, n (%) 1 (2.8) 463 (50.9)
RCA, n (%) 7 (19.4) 221 (24.3)
DS ≥50% by 3D QCA, n (%) 24 (66.7) 43 (4.7) <0.001
Values are mean±SD or number (percentage). 3D indicates 3- dimensional; BMI, body mass index; CAD, coronary artery disease; DS, diameter stenosis; 
LAD, left anterior descending; LCX, left circumflex; LM, left main; MI SYNTAX, Myocardial Infarction TAXus and Cardiac Surgery; PCI, percutaneous coronary 
intervention; QCA, quantitative coronary angiography; RCA, right coronary artery; and QFR, quantitative flow ratio.
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median follow- up of 2.5 years (interquartile range, 1.3– 
4.3  years). Cardiac death occurred numerically more 
frequently but CIs were wide and risk estimates were 
imprecise (8.6% versus 4.7%, respectively; HR, 1.92 
[95% CI, 0.58– 6.33], P=0.284). Rates of any sponta-
neous MI (22.4% versus 5.8%, respectively; HR, 4.38 
[95% CI, 1.93– 9.92], P<0.001) and any revasculariza-
tion (58.6% versus 15.0%, respectively; HR, 5.17 [95% 
CI, 3.14– 8.52], P<0.001) were significantly higher in the 
QFR ≤0.80 group. Consistently, exploratory end points 
of cardiac death, any spontaneous MI, and any revas-
cularization (62.9% versus 18.8%, respectively; HR, 
4.68 [95% CI, 2.96– 7.41], P<0.001) as well as cardiac 
death and any spontaneous MI (29.6% versus 9.7%, 
respectively; HR, 3.58 [95% CI, 1.82– 7.02], P<0.001) 
showed significantly higher rates in the QFR ≤0.80 
group (Table 3).
When applying a landmark analysis at 1  year, re-
sults for the primary end point and its components re-
mained fully consistent (Table S1).
We performed a sensitivity analysis considering only 
patients with at least one >30% stenosis (Tables  S2 
through S6 and Figures S2 through S4). Results for this 
population (QFR ≤0.80 n=35 versus QFR >0.80 n=412) 
were consistent with those of the overall study cohort.
Independent Predictor Analysis
In multivariable analysis there was a significant asso-
ciation between QFR ≤0.80 and the primary end point, 
with a 7.8 times higher expected hazard for patients 
with QFR ≤0.80 (P<0.001). Further independent pre-
dictors of the primary end point in multivariable analy-
sis were MI SYNTAX score (per 5- point increase) and 
left ventricular ejection fraction but not DS ≥50% by 3D 
QCA (Table 4). Results for the population including only 
>30% stenosis were fully consistent (Table S5).
Diagnostic Performance of QFR
Using the conventional QFR cutoff point of ≤0.80 for 
the prediction of the primary end point (cardiac death, 
spontaneous non– TV- MI, non- TVR) at 5 years, accu-
racy was 86.2%, sensitivity was 23.4%, specificity was 
Figure 3. Scatterplot diameter stenosis vs quantitative 
flow ratio (QFR; vessel- level).
LAD indicates left anterior descending; LCX, left circumflex; and 
RCA, right coronary artery.
Table 2. Three- Dimensional QCA Analysis
Three- Dimensional QCA Variable 
(Patient- Level) QFR ≤0.80 (n=35) QFR >0.80 (n=582) P Value
Diameter stenosis, % 54.2±8.1 35.4±9.6 <0.001
Area stenosis, % 69.9±8.3 45.9±15.0 <0.001
Lesion length, mm 31.0±16.9 19.9±13.2 <0.001
Proximal diameter, mm 2.77±0.61 2.90±0.63 0.264
Minimal lumen diameter, mm 1.33±0.37 1.89±0.50 <0.001
Distal diameter, mm 2.46±0.49 2.62±0.65 0.170
Reference diameter, mm 2.88±0.54 2.92±0.66 0.702
Three- Dimensional QCA Variable 
(Vessel- Level) QFR ≤0.80 (n=36) QFR >0.80 (n=910) P Value
Diameter stenosis, % 54.2±8.1 33.3±9.6 <0.001
Area stenosis, % 69.9±8.1 42.5±15.6 <0.001
Lesion length, mm 30.4±17.0 18.6±13.1 <0.001
Proximal diameter, mm 2.75±0.62 2.86±0.64 0.333
Minimal lumen diameter, mm 1.32±0.37 1.92±0.51 <0.001
Distal diameter, mm 2.45±0.49 2.60±0.65 0.177
Reference diameter, mm 2.86±0.55 2.88±0.66 0.797
Values are mean±SD. QCA indicates quantitative coronary angiography; and QFR, quantitative flow ratio.
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97.5%, PPV was 62.9%, and NPV was 87.6%. ROC 
analysis yielded an AUC of 0.64 (95% CI, 0.58– 0.70) 
(Figure 5). Expressed in absolute patient numbers, in 
532 of 617 (86.2%) patients, QFR ≤0.80 versus QFR 
>0.80 correctly identified patients with versus those 
without a subsequent event (ie, occurrence of the 
Table 3. Clinical Outcomes at 5 Years
QFR ≤0.80 (n=35) QFR >0.80 (n=582) HR (95% CI) P Value
Cardiac death, non– TV- MI, non- TVR, n (%) 22 (62.9) 72 (12.5) 7.33 (4.54– 11.83) <0.001
Cardiac death, MI (any), revascularization (any), n (%) 22 (62.9) 108 (18.8) 4.68 (2.96– 7.41) <0.001
Cardiac death or MI (any), n (%) 10 (29.6) 55 (9.7) 3.58 (1.82– 7.02) <0.001
Cardiac death, TV- MI, TVR, n (%) 13 (37.5) 74 (12.9) 3.50 (1.94– 6.30) <0.001
Death, n (%) 4 (11.4) 54 (9.3) 1.28 (0.46– 3.54) 0.631
Cardiac death, n (%) 3 (8.6) 27 (4.7) 1.92 (0.58– 6.33) 0.284
Non– TV- MI, n (%) 4 (12.8) 17 (3.1) 4.38 (1.47– 13.02) 0.008
Non- TVR, n (%) 19 (58.6) 43 (7.7) 10.99 (6.39– 18.91) <0.001
Revascularization (any), n (%) 19 (58.6) 85 (15.0) 5.17 (3.14– 8.52) <0.001
MI (any), n (%) 7 (22.4) 32 (5.8) 4.38 (1.93– 9.92) <0.001
MI Q wave, n (%) 3 (9.2) 9 (1.6) 5.96 (1.61– 22.03) 0.007
MI non– Q wave, n (%) 5 (16.4) 25 (4.6) 3.88 (1.49– 10.15) 0.006
Stroke (any), n (%) 3 (9.0) 12 (2.2) 4.37 (1.23– 15.50) 0.022
Depicted are number of patients (percentage) and hazard ratios (HRs) with 95% CI from univariable Cox proportional hazards regressions with P values. MI 
indicates myocardial infarction; non– TV- MI, nontarget vessel myocardial infarction; non- TVR, nontarget vessel revascularization; QFR, quantitative flow ratio; 
TV- MI, target vessel myocardial infarction; and TVR, target vessel revascularization.
Figure 4. Kaplan- Meier curves of the primary end point.
Cumulative incidence curves from Cox proportional hazards models through 5  years for (A) primary end point: cardiac death, 
spontaneous nontarget vessel myocardial infarction (non– TV- MI), and nontarget vessel revascularization (non- TVR); (B) cardiac death, 
(C) non- TVR, and (D) spontaneous non– TV- MI. HR indicates hazard ratio; and QFR, quantitative flow ratio.
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primary end point), whereas in 72 of 617 (11.7%) pa-
tients, QFR was >0.80 despite a subsequent event 
(false- negatives), and in 13 of 617 (2.1%) patients, 
QFR was ≤0.80 although no event occurred (false- 
positives). The best QFR cutoff to predict the primary 
end point was 0.93 with accuracy of 64.2%, sensitiv-
ity of 55.3%, specificity of 65.8%, PPV of 22.5%, and 
NPV of 89.1%. Results for the population including only 
>30% stenosis were comparable with slightly higher 
sensitivity (27.8%) at the cost of marginally lower speci-
ficity (96.5%) (Table S7 and Figure S3).
To account for changing event risk over time, we 
additionally performed time- dependent ROC analysis 
at 1, 2, 3, 4, and 5 years, which showed similar results 
(AUC range, 0.61– 0.64) (Figure S5). As a comparator 
to QFR ≤0.80, we added the diagnostic ability of DS 
≥50% by 3D QCA (Figure S6), which yielded markedly 
lower PPV (32.8%) for DS ≥50% as compared with 
QFR ≤0.80 (62.9%) but similar AUC (DS ≥50% 0.65 
[0.59– 0.72] and QFR ≤0.80 0.64 [0.58– 0.70]).
Three- Dimensional QCA and QFR of 
Treated Nontarget Vessels
As a comparison, 3D QCA and QFR were also as-
sessed in the nontarget vessels that were treated 
either during the index procedure or as a planned 
staged procedure. Of 128 vessels of 105 patients, 89 
vessels of 79 patients were eligible for QFR measure-
ment (Figure S7). Mean DS% was 54.2% (±12.4, range 
26.2%– 92.0%) and mean QFR was 0.80 (±11, range 
0.40– 0.99) (Figures  S8 and S9). Compared with the 
nontarget vessels that were left untreated, QFR was 
significantly lower (P<0.001) and DS% was significantly 
higher (P<0.001) (Table S8). A total of 49.4% (n=44) of 
vessels had QFR ≤0.80 (Table S9).
QFR Distribution in Untreated Nontarget 
Vessels With a Non- TVR Event
Of 109 vessels of 62 patients with non- TVR during 
5 years of follow- up, matched 2D QCA from the non- 
TVR angiographies and QFR values from the baseline 
angiographies were available in 51 (46.8%) vessels of 
33 (53.2%) patients (Figure S10). A total of 36 (70.6%) 
vessels had DS% ≥50% with ischemia and 15 (29.4%) 
had DS% ≥70%. In vessels with 2D QCA, DS% ≥50%, 
and ischemia at the timepoint of the non- TVR event, 
mean QFR calculated from baseline angiography was 
0.84 (±0.13, range 0.49– 1.00). In vessels with 2D QCA 
DS% ≥70% at the timepoint of the non- TVR event, 
mean QFR calculated from baseline angiography was 
0.86 (±0.14, range 0.48– 1.00) (Table S10).
DISCUSSION
The salient findings of our study can be summarized 
as follows: In patients with STEMI undergoing primary 
PCI and angiography- guided complete revasculariza-
tion, QFR ≤0.80 in nontarget vessels was associated 
with a 7 times higher rate of the primary end point 
of cardiac death, spontaneous non– TV- MI, and non- 
TVR at 5  years. Differences were driven by a 4- fold 
increased rate of spontaneous non– TV- MI and an 11- 
fold increased rate of non- TVR. Multivariable analysis 
identified QFR ≤0.80 but not DS ≥50% by 3D QCA, 
Table 4. Independent Predictor Analysis
Primary End Point 
(Cardiac Death, Non– TV- MI, Non- TVR)
Univariable Analysis 
n=617 
HR (95% CI) P Value
Multivariable Analysis 
n=571 
HR (95% CI) P Value
Female sex 1.23 (0.78– 1.94) 0.374
Age, y (per 1- y increase) 1.03 (1.02– 1.05) <0.001 1.02 (1.00– 1.04) 0.061
BMI, kg/m2 (per 1- kg/m2 increase) 1.02 (0.97– 1.07) 0.515
Diabetes mellitus 2.15 (1.34– 3.43) 0.001 1.63 (0.95– 2.83) 0.079
Hypertension 1.66 (1.11– 2.50) 0.015 1.14 (0.71– 1.84) 0.588
Hypercholesterolemia 1.26 (0.83– 1.92) 0.277
Family history of CAD 0.83 (0.53– 1.29) 0.402
Killip III or IV 7.71 (2.83– 20.99) <0.001 3.03 (0.89– 10.33) 0.077
Left ventricular function, % (per 5% decrease) 1.29 (1.17– 1.43) <0.001 1.25 (1.13– 1.39) <0.001
MI SYNTAX score (per 5 points increase) 1.39 (1.25– 1.54) <0.001 1.19 (1.05– 1.34) 0.007
QFR ≤0.80 7.33 (4.54– 11.83) <0.001 7.75 (3.89– 15.42) <0.001
DS ≥50% by 3D QCA 2.63 (1.59– 4.35) <0.001 0.60 (0.28– 1.28) 0.187
Results from univariable and multivariable Cox proportional hazard analyses. Depicted are estimated hazard ratios (HRs) with 95% CI of the primary 
end point (cardiac death, spontaneous nontarget vessel myocardial infarction [non– TV- MI], nontarget vessel revascularization [non- TVR]) for patient baseline 
characteristics, quantitative flow ratio (QFR) ≤0.80, and diameter stenosis (DS) ≥50% by 3- dimensional (3D) quantitative coronary angiography (QCA). 
Multivariable analysis was performed for variables with a significant association with the primary end point in univariable analysis. BMI indicates body mass 
index; CAD, coronary artery disease; and MI SYNTAX, Myocardial Infarction TAXus and Cardiac Surgery.
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as an independent predictor for the occurrence of the 
primary end point. The conventional QFR cutoff ≤0.80 
showed high specificity (97.5%) and good NPV (87.6%) 
but low sensitivity (23.4%) and moderate PPV (62.9%) 
in the prediction of the primary end point. The pre-
sent study including 617 patients and 946 vessels is 
the largest data set published on QFR in patients with 
STEMI.
QFR Versus Angiography
Angiography- guided complete revascularization in pa-
tients with STEMI with multivessel disease has been 
shown to significantly reduce the composite end point 
of cardiovascular death and MI throughout 3 years me-
dian follow- up (HR, 0.74; 95% CI, 0.60– 0.91 [P=0.004]) 
in the COMPLETE trial. In this study, revascularization 
was performed if nontarget vessel stenosis exceeded 
70% by visual estimate or was ≥50% to 69% if addi-
tionally performed FFR amounted to ≤0.80.12 The latter 
occurred in <1% of enrolled patients, and, therefore, 
identification of NCL requiring revascularization in the 
COMPLETE trial may be regarded as angiography- 
guided. Two RCTs investigating FFR- guided com-
plete revascularization versus culprit- only PCI among 
patients with acute MI and multivessel disease, the 
DANAMI- 3- PRIMULTI (Complete Revascularisation 
Versus Treatment of the Culprit Lesion Only in Patients 
With ST- Segment Elevation Myocardial Infarction 
and Multivessel Disease)7 and COMPARE ACUTE 
(Comparison Between FFR Guided Revascularization 
Versus Conventional Strategy in Acute STEMI Patients 
With MVD) trials,8 showed better outcomes with FFR- 
guided complete revascularization (treatment if FFR 
≤0.80). Of note, results were driven by a reduction in 
repeat revascularization with no differences for hard 
outcomes (MI or death) alone. Furthermore, patient se-
lection in both trials used angiography guidance in a 
first step, as eligibility for randomization was based on 
≥50% stenosis by visual estimate.
Our study analysis suggests that QFR in addition 
to angiographic assessment identifies patients at risk 
for future nontarget vessel– related adverse events 
including spontaneous MI and revascularization in a 
patient population of patients with STEMI undergoing 
angiography- guided complete revascularization. The 
lowest DS% in the group of patients with QFR ≤0.80 
was 42%, suggesting that patients with STEMI may 
possibly not only benefit from treatment of stenoses 
≥70% or ≥50% and positive FFR ≤0.80 but also of 
lower grade stenoses in the range of ≥40% to 70% 
in the presence of a positive QFR ≤0.80. Interestingly, 
among the nontarget vessels that were treated either 
during the index or as a planned staged procedure, 
49.4% exhibited QFR ≤0.80.
However, it is currently unknown whether the patho-
physiology of recurrent NCL events in acute coronary 
syndrome (ACS) is related to the degree of stenosis, 
its functional significance, or the plaque composition 
itself.32 Thus, the definite role of any physiologic as-
sessment in NCL among patients with acute coronary 
syndrome remains to be established with appropri-
ate large- scale RCT data. For FFR, a respective trial 
(FLOWER- MI) comparing an angiography- guided ver-
sus FFR- guided NCL revascularization strategy in pa-
tients with STEMI is ongoing. For QFR, 2 RCTs (FAVOR 
III China [NCT03656848] and FAVOR III Europe Japan 
[NCT03729739]) are investigating angiography- guided 
versus QFR- guided PCI in stable patients, but, to our 
knowledge, there are no ongoing RCTs in patients with 
acute coronary syndrome.
In our study, 33% (n=12) of vessels in the QFR ≤0.80 
group exhibited <50% stenosis, 67% (n=24) exhibited 
≥50% to 70% stenosis, and the majority of vessels (67%) 
Figure 5. Receiver operating curve (ROC) analysis for the 
primary end point.
Results of ROC analysis for the prediction of the primary 
end point at 5  years (cardiac death, spontaneous nontarget 
vessel myocardial infarction [non– TV- MI], nontarget vessel 
revascularization [non- TVR]). AUC indicates area under the 
curve; and QFR, quantitative flow ratio.
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exhibited diffuse disease (ie, lesion length >20  mm), 
which may explain why the significance was under-
estimated based on angiographic criteria alone. Of 
note, diffuse disease may be less amenable to revas-
cularization and thus limit realizable treatment options. 
Mismatch between angiographic and functional lesion 
severity (ie, QFR ≤0.80 but DS <50%) occurred most 
frequently (83%) in the left anterior descending artery, 
which is in line with previous FFR investigations.33
Previous studies have shown that QFR outperforms 
2D QCA17,18 and 3D QCA outperforms 2D QCA34 in the 
prediction of FFR ≤0.80. In our study, as QFR ≤0.80 
and DS ≥50% by 3D QCA had similar sensitivity and 
specificity for the detection of the primary clinical end 
point, ROC analysis also yielded similar AUCs for QFR 
and DS%. However, QFR ≤0.80 proved to be the better 
predictive variable, as shown by the markedly higher 
PPV for QFR ≤0.80 than for DS ≥50% (62.9% versus 
32.8%, respectively). This was also confirmed in mul-
tivariable analysis, where only QFR ≤0.80 but not DS 
≥50% was independently associated with the primary 
end point.
Clinical Events
The results for the present study are in line with 2 previ-
ous QFR studies, which showed a 2- to 3- fold increase 
in the rate of patient- oriented major adverse cardiac 
events at 2 and 5 years20,35 in patients with functionally 
incomplete revascularization based on QFR ≤0.80. At 
variance to these studies, the end point selection in 
our study focused on nontarget vessel– related events, 
allowing for a more direct mechanistic assessment of 
the association between the QFR value and the ad-
verse events. Indeed, our results revealed that in the 
QFR ≤0.80 group, 71.4% (n=5) of MIs were related to 
the vessel with QFR ≤0.80. Furthermore, we extended 
QFR calculation to all eligible nontarget vessels, 
whereas in previous studies, QFR was calculated for 
stenoses ≥50% by visual estimate.20,35 This might be 
laborious, but in view of new methods like artificial intel-
ligence, routine implementation of this approach might 
be possible. Alternatively, our data also support a less 
extreme approach using >30% stenosis as a cutoff for 
QFR analysis, as results for this subpopulation were 
similar compared with the overall study results.
Application of QFR
Collectively, the current evidence on QFR in NCLs of 
patients with STEMI suggests a diagnostic and prog-
nostic incremental benefit over angiography alone. 
It is noteworthy that the safe and noninvasive QFR 
procedure is able to predict future adverse events in-
cluding spontaneous MI and revascularization related 
to NCLs without the need of additional measures be-
yond diagnostic angiography and dedicated software, 
which may be of particular importance to streamline 
the effective workflow for patients with STEMI. As an 
important limitation to the widespread use of QFR, it 
has to be acknowledged that QFR calculation in our 
retrospective data set was possible in only 56% of pa-
tients. However, in previous targeted prospective stud-
ies, QFR calculation was possible in 96% to 99% of 
cases.17,18
In this STEMI population, the NPV of QFR >0.80 to 
preclude the primary end point was high (87.6%), but 
further prospective research is warranted to investigate 
whether revascularization of lesions with QFR >0.80 in 
this setting can safely be deferred. The moderate PPV 
of QFR ≤0.80 to predict primary end point events may 
be at least in part related to the low number of lesions 
with QFR ≤0.80 (n=36, 5.7%). Furthermore, the low 
sensitivity to detect the primary end point may reflect 
the low prevalence of higher grade stenoses (mean 
DS 36.5% [±10.5]). When conducting ROC analysis in-
cluding only patients with higher degrees of stenosis 
(>25%, >30%, >40%, >50%), sensitivity incrementally 
increased, reaching a maximum of 76.2% in stenoses 
>50% (Table S7, Figure S3). The best QFR cutoff to de-
tect the primary end point was 0.93, which may war-
rant further investigation in future studies.
Limitations and Strengths
This study trial is a retrospective post hoc analysis 
and therefore optimal angiographic projections for 
QFR calculation were not always available. QFR was 
computable in only 56.1% of patients mostly because 
of missing isocenter calibration or inadequate angio-
graphic quality, aspects that can be addressed, as 
shown in previous prospective studies (successful 
QFR calculation in 96% to 99% of vessels).17,18 The 
study population consisted of unbalanced compara-
tor groups, which may weaken the reliability of the 
statistical analyses, led to wide CIs, and, owing to 
the low event number in the large QFR >0.80 group, 
might have biased the overall study results away from 
the null hypothesis. However, we addressed this by 
performing all analyses including only patients with 
>30% stenosis, and results for this lesser skewed 
were consistent with the overall study results. 
Furthermore, the study design of a QFR investiga-
tion regardless of DS was chosen to investigate the 
benefit of a truly physiologic assessment without an 
angiographic/QCA stenosis preselection, which is, to 
our knowledge, unique in the field of QFR. Lesions 
left untreated according to an angiographic assess-
ment could consist of more complex lesions less/not 
amenable to revascularization, which would affect 
the practical implications of QFR detecting these le-
sions. As the original study design included no FFR 
analyses, comparison between QFR and FFR was 
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not possible and therefore no statement regarding 
the accuracy of QFR as compared with FFR in the 
setting of STEMI can be made. However, previous 
studies addressed this question sufficiently.20– 23 The 
strengths of our study are the randomized controlled 
multicenter design, independent event adjudication, 
QFR analysis blinded for patient outcomes, follow-
 up duration of 5  years, and the sample size of 617 
patients and 946 vessels, representing, to our knowl-
edge, the largest data set published on QFR in pa-
tients with STEMI.
CONCLUSIONS
The findings of the present study suggest an incre-
mental diagnostic and prognostic value of QFR for 
NCL assessment in patients with STEMI undergoing 
angiography- guided complete revascularization.
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SUPPLEMENTAL MATERIAL 





HR (95% CI) p-value
Cardiac death, non-TV-MI, non-
TVR, n (%) 
 10 (43.5)  42 (7.8) 6.68 (3.35-13.33) <0.001 
Cardiac death, MI (any), 
revascularization (any)  
 10 (43.5)  63 (12.0) 4.16 (2.14-8.12) <0.001 
Cardiac death or MI (any)   4 (14.7)  33 (6.1) 2.53 (0.90-7.15) 0.079 
Cardiac death, TV-MI, TVR, n (%)   4 (15.9)  42 (7.8) 2.00 (0.72-5.56) 0.187 
Death, n (%)   1 (3.1)  38 (6.7) 0.46 (0.06-3.32) 0.439 
Cardiac death, n (%)   0 (0.0)  13 (2.3) - - 
Non-TV-MI, n (%)   3 (10.0)  14 (2.6) 4.06 (1.17-14.12) 0.028 
Non-TVR, n (%)  10 (43.5)  29 (5.4) 9.75 (4.75-20.04) <0.001 
Revascularization (any), n (%)  10 (43.5)  50 (9.6) 5.25 (2.66-10.37) <0.001 
MI (any), n (%)   4 (14.7)  23 (4.3) 3.65 (1.26-10.54) 0.017 
MI Q-wave, n (%)   2 (6.5)   6 (1.1) 6.02 (1.21-29.82) 0.028 
MI non Q-wave, n (%)   3 (11.0)  19 (3.6) 3.18 (0.94-10.74) 0.063 
Stroke (any), n (%)   1 (3.3)   9 (1.7) 1.96 (0.25-15.48) 0.523 
Depicted are number of patients (%) and hazard ratios (HR) with 95% confidence intervals 
(CI) from univariable Cox proportional hazards regressions with p-values. MI = myocardial
infarction, non-TV-MI = non-target vessel myocardial infarction, non-TVR = non-target vessel 
revascularization, TV-MI = target vessel myocardial infarction, TVR = target vessel 
revascularization, QFR = Quantitative Flow Ratio. 






Patient characteristics (patient-level) 
Sex (female), n (%) 10 (28.6) 96 (23.3) 0.534 
Age, years 63.1 ±11.4 61.7 ±11.6 0.499 
BMI, kg/m2 27.3 ±3.5 27.1 ±4.0 0.764 
Diabetes mellitus, n (%) 8 (22.9) 59 (14.3) 0.213 
Hypertension, n (%) 22 (62.9) 203 (49.3) 0.159 
Hypercholesterolemia, n (%) 25 (71.4) 224 (54.8) 0.075 
Family history of CAD, n (%) 13 (38.2) 122 (30.0) 0.335 
Killip I or II, n (%) 33 (94.3) 409 (99.3) 0.051 
Killip IV, n (%) 1 (2.9) 2 (0.5) 0.217 
Left ventricular function, % 49.1 ±10.4 48.7 ±10.5 0.853 
MI SYNTAX Score 16.2 ±10.9 11.4 ±7.71 <0.001 
Procedural characteristics (patient-level) 
Infarct vessel 
0.010 
Left main (LM), n (%) 0 (0.0) 1 (0.2) 
Left anterior descending (LAD), n (%) 5 (14.3) 165 (40.0) 
Left circumflex (LCX), n (%) 7 (20.0) 62 (15.0) 
Right coronary artery (RCA), n (%) 23 (65.7) 184 (44.7) 
Number of lesions in infarct vessel, n 1.03 ±0.17 1.12 ±0.37 0.141 
Table S2. continued 
Type of intervention 
0.217 
PCI - implantation of stent(s), n (%) 34 (97.1) 410 (99.5) 
PCI - only balloon dilatation, n (%) 1 (2.9) 2 (0.5) 
Number of stents per lesion, n 1.37 ±0.81 1.43 ±0.73 0.642 
Total stent length per lesion, mm 28.4 ±15.5 27.1 ±13.4 0.578 
Average stent diameter, mm 3.24 ±0.44 3.17 ±0.41 0.352 
Direct stenting, n (%) 11 (32.4) 112 (27.3) 0.552 
Maximal balloon pressure, atm 16.3 ±3.5 15.4 ±3.2 0.099 
Thrombus aspiration, n (%) 23 (65.7) 244 (59.2) 0.479 
Non-target vessel (patient-level) N=35 N=412 <0.001 
Left anterior descending (LAD), n (%) 27 (77.1) 133 (32.3) 
Left circumflex (LCX), n (%) 1 (2.9) 173 (42.0) 
Right circumflex (RCA), n (%) 7 (20.0) 106 (25.7) 
DS ≥50% by 3D-QCA, n (%) 23 (65.7) 38 (9.2) <0.001 
Non-target vessel (vessel-level) N=36 N=542 <0.001 
Left anterior descending (LAD), n (%) 28 (77.8) 153 (28.2) 
Left circumflex (LCX), n (%) 1 (2.8) 256 (47.2) 
Right circumflex (RCA), n (%) 7 (19.4) 133 (24.5) 
DS ≥50% by 3D-QCA, n (%) 24 (66.7) 43 (7.9) <0.001 
Values are mean±SD or n (%). BMI = body mass index, CAD = coronary artery disease, DS% 
= diameter stenosis, MI SYNTAX Score = Myocardial Infarction TAXus and Cardiac 
Surgery Score, PCI = percutaneous coronary intervention, 3D-QCA = 3D-Quantitative 
Coronary Angiography. 








Diameter stenosis, % 54.2 ±8.1 40.1 ±7.1 <0.001 
Area stenosis, % 69.9 ±8.3 52.6 ±11.4 <0.001 
Lesion length, mm 31.0 ±16.9 22.3 ±13.8 <0.001 
Proximal diameter, mm 2.77 ±0.61 2.93 ±0.64 0.155 
Minimal lumen diameter, mm 1.33 ±0.37 1.77 ±0.45 <0.001 
Distal diameter, mm 2.46 ±0.49 2.62 ±0.65 0.169 








Diameter stenosis, % 54.2 ±8.0 39.5 ±6.8 <0.001 
Area stenosis, % 69.9 ±8.1 51.9 ±11.2 <0.001 
Lesion length, mm 30.4 ±17.0 22.0 ±13.8 <0.001 
Proximal diameter, mm 2.75 ±0.62 2.92 ±0.64 0.124 
Minimal lumen diameter, mm 1.32 ±0.37 1.78 ±0.44 <0.001 
Distal diameter, mm 2.45 ±0.49 2.60 ±0.65 0.162 
Reference diameter, mm 2.86 ±0.55 2.94 ±0.65 0.453 
Values are mean±SD. DS% = diameter stenosis, QFR = Quantitative Flow Ratio, 
3D-QCA = 3D-Quantitative Coronary Angiography. 





HR (95% CI) p-value
Cardiac death, non-TV-MI, 
non-TVR, n (%)  
 22 (62.9)  57 (14.0) 6.61 (4.03-10.84) <0.001 
Cardiac death, MI (any), 
revascularization (any), n (%) 
 22 (62.9)  81 (19.9) 4.48 (2.80-7.19) <0.001 
Cardiac death or MI (any), n (%)  10 (29.6)  42 (10.4) 3.34 (1.67-6.65) 0.001 
Cardiac death, TV-MI, TVR, n (%)  13 (37.5)  53 (13.0) 3.48 (1.90-6.38) <0.001 
Death, n (%)   4 (11.4)  41 (10.0) 1.20 (0.43-3.34) 0.733 
Cardiac death, n (%)   3 (8.6)  21 (5.2) 1.75 (0.52-5.86) 0.366 
Non-TV-MI, n (%)   4 (12.8)  15 (3.9) 3.52 (1.17-10.60) 0.025 
Non-TVR, n (%)  19 (58.6)  35 (8.9) 9.58 (5.46-16.79) <0.001 
Revascularization (any), n (%)  19 (58.6)  63 (15.8) 4.99 (2.98-8.35) <0.001 
MI (any), n (%)   7 (22.4)  24 (6.2) 4.15 (1.79-9.64) 0.001 
MI Q-wave, n (%)   3 (9.2)   4 (1.0) 9.54 (2.14-42.63) 0.003 
MI non Q-wave, n (%)   5 (16.4)  21 (5.4) 3.24 (1.22-8.59) 0.018 
Stroke (any), n (%)   3 (9.0)   7 (1.8) 5.27 (1.36-20.37) 0.016 
Depicted are number of patients (%) with ≥1 DS >30% and hazard ratios (HR) with 95% confidence 
intervals (CI) from Cox regressions with p-values. MI = myocardial infarction, non-TV-MI = non-target 
vessel myocardial infarction, non-TVR = non-target vessel revascularization, TV-MI = target vessel 
myocardial infarction, TVR = target vessel revascularization, QFR = Quantitative Flow Ratio. 
Table S5. Independent Predictor Analysis for >30% DS. 




HR (95% CI) 
p-value Multivariable analysis 
N=447 
HR (95% CI) 
p-value
Sex (female) 1.36 (0.83-2.20) 0.219 
Age, years 
(per 1 year increase) 
1.03 (1.01-1.05) 0.001 1.02 (1.00-1.04) 0.047 
BMI, kg/m2
(per 1 kg/m2 increase) 
1.02 (0.96-1.07) 0.570 
Diabetes mellitus 2.04 (1.23-3.39) 0.006 1.59 (0.89-2.86) 0.120 
Hypertension 1.70 (1.08-2.69) 0.021 1.20 (0.71-2.04) 0.489 
Hypercholesterolemia 1.33 (0.84-2.10) 0.228 
Family history of CAD 1.06 (0.66-1.71) 0.800 
Killip III or IV 7.38 (2.33-23.40) 0.001 2.39 (0.55-10.50) 0.247 
Left ventricular function, % 
(per 5% decrease) 
1.29 (1.16-1.43) <0.001 1.28 (1.15-1.43) <0.001 
MI SYNTAX Score 
(per 5 points increase) 
1.31 (1.17-1.47) <0.001 1.10 (0.95-1.26) 0.198 
QFR ≤0.80 6.61 (4.03-10.84) <0.001 7.60 (3.85-15.04) <0.001 
DS ≥50% by 3D-QCA 2.27 (1.36-3.81) 0.002 0.64 (0.31-1.36) 0.247 
Results from univariable and multivariable Cox proportional analyses for patients with ≥1 DS >30%. Depicted are 
estimated hazard ratios (HR) with 95% confidence intervals (CI) of the primary endpoint (cardiac death, non-TV-MI, 
non-TVR) for patient baseline characteristics, QFR ≤0.80, and DS ≥50% by 3D-QCA. Multivariable analysis was 
performed for variables with a significant association with the primary endpoint in univariable analysis. BMI = body 
mass index, CAD = coronary artery disease, DS% = diameter stenosis by 3D-QCA, MI SYNTAX Score = Myocardial 
Infarction TAXus and Cardiac Surgery Score, non-TV-MI = non-target vessel myocardial infarction, non-TVR = non-
target vessel revascularization, QFR = Quantitative Flow Ratio, 3D-QCA = 3D-Quantiative Coronary Angiography.





HR (95% CI) p-value
Cardiac death, non-TV-MI, non-
TVR, n (%) 
 10 (43.5)  42 (7.8) 6.68 (3.35-13.33) <0.001 
Cardiac death, MI (any), 
revascularization (any)  
 10 (43.5)  63 (12.0) 4.16 (2.14-8.12) <0.001 
Cardiac death or MI (any)   4 (14.7)  33 (6.1) 2.53 (0.90-7.15) 0.079 
Cardiac death, TV-MI, TVR, n (%)   4 (15.9)  42 (7.8) 2.00 (0.72-5.56) 0.187 
Death, n (%)   1 (3.1)  38 (6.7) 0.46 (0.06-3.32) 0.439 
Cardiac death, n (%)   0 (0.0)  13 (2.3) - - 
Non-TV-MI, n (%)   3 (10.0)  14 (2.6) 4.06 (1.17-14.12) 0.028 
Non-TVR, n (%)  10 (43.5)  29 (5.4) 9.75 (4.75-20.04) <0.001 
Revascularization (any), n (%)  10 (43.5)  50 (9.6) 5.25 (2.66-10.37) <0.001 
MI (any), n (%)   4 (14.7)  23 (4.3) 3.65 (1.26-10.54) 0.017 
MI Q-wave, n (%)   2 (6.5)   6 (1.1) 6.02 (1.21-29.82) 0.028 
MI non Q-wave, n (%)   3 (11.0)  19 (3.6) 3.18 (0.94-10.74) 0.063 
Stroke (any), n (%)   1 (3.3)   9 (1.7) 1.96 (0.25-15.48) 0.523 
Depicted are number of patients (%) with ≥1 DS >30% and hazard ratios (HR) with 95% 
confidence intervals (CI) from Cox regressions with p-values. MI = myocardial infarction, non-
TV-MI = non-target vessel myocardial infarction, non-TVR = non-target vessel revascularization, 
TV-MI = target vessel myocardial infarction, TVR = target vessel revascularization, QFR = 
Quantitative Flow Ratio. 












QFR (mean) 0.93 ±0.09 0.92 ±0.09 0.91 ±0.1 0.85 ±0.11 0.76± 0.15 
Diameter stenosis, % 36.5 ±10.5 38.7±9.1 41.1±8.2 47.4±6.6 55.8±5.8 
Accuracy, % 86.2 86.0 84.3 79.7 78.1 
Sensitivity, % 23.4 25.9 27.8 40.0 76.1 
Specificity, % 97.5 97.1 96.5 92.4 79.1 
Positive predictive value, % 62.9 62.9 62.9 62.9 64.0 
Negative predictive value, % 87.6 87.5 86.2 82.8 87.2 
Values are mean±SD. DS% = diameter stenosis, QFR = Quantitiative Flow Ratio. 
Table S8. 3D-QCA and QFR in Treated vs. Untreated Non-
Target Vessels. 









QFR 0.80 ±0.11 0.95 ±0.08 <0.001 
Diameter stenosis, % 54.2 ±12.4 34.1 ±10.4 <0.001 
Area stenosis, % 70.7 ±14.7 43.5 ±16.2 <0.001 
Lesion length, mm 19.8 ±10.9 19.1 ±13.5 0.609 
Proximal diameter, mm 2.74 ±0.63 2.85 ±0.63 0.122 
Minimal lumen diameter, mm 1.23 ±0.42 1.90 ±0.52 <0.001 
Distal diameter, mm 2.43 ±0.57 2.59 ±0.64 0.024 
Reference diameter, mm 2.69 ±0.59 2.88 ±0.66 0.009 
Values are mean±SD. DS% = diameter stenosis, non-TV = non-target vessel, QFR = 
Quantitative Flow Ratio, 3D-QCA = 3D-Quantitative Coronary Angiography. 




QFR ≤0.80 QFR >0.80 Total 
Treated non-TV, n (%) 44 (49.4) 45 (50.6) 89 (100) 
Untreated non-TV, n (%) 36 (3.8) 910 (96.2) 946 (100) 
Values are n (%) vessels. Non-TV = non-target vessel, QFR = Quantitative Flow Ratio. 
Table S10. Baseline QFR and 3D-QCA Values of Vessels with a Non-
TVR Event. 
QFR and 3D-QCA variable 
(vessel-level) 
DS% ≥50% by 2D-
QCA with ischemia 
(N= 36) 
DS% ≥70% by 2D-
QCA 
(N=15)   
p-value
QFR 0.84 ±0.13 0.86 ±0.14 0.678 
Diameter stenosis, % 42.0 ±9.1 41.7 ±11.6 0.918 
Area stenosis, % 57.5 ±11.9 58.6 ±14.1 0.757 
Lesion length, mm 22.5 ±15.3 28.1 ±17.4 0.260 
Proximal diameter, mm 2.70 ±0.55 2.82 ±0.71 0.496 
Minimal lumen diameter, mm 1.66 ±0.37 1.86 ±0.38 0.086 
Distal diameter, mm 2.49 ±0.49 2.60 ±0.50 0.486 
Reference diameter, mm 2.87 ±0.54 3.21 ±0.47 0.036 
Values are mean±SD. Shown are QFR and 3D-QCA values calculated from the baseline 
angiography according to DS% ≥50% by 2D-QCA with ischemia or DS% ≥70% by 2D-QCA 
at the timepoint of the non-TVR event. DS% = diameter stenosis, non-TV = non-target vessel, 
QFR = Quantitative Flow Ratio, 3D-QCA = 3D-Quantitative Coronary Angiography. 
Figure S1. Distribution of DS% (vessel-level).
Distribution of DS% on vessel-level (n=946). DS% = diameter stenosis. 
Distribution of QFR values on vessel-level for whole study cohort (n=946) (left) and >30% stenosis 
(n=578) (right). DS% = diameter stenosis, QFR = Quantitative Flow Ratio.  
Figure S2. Distribution of QFR Values (vessel-level). 
AUC = area under the curve, DS% = diameter stenosis, QFR = Quantitative Flow 
Ratio. 
Figure S3.  ROC Analyses for the Prediction of the Primary Endpoint for Different DS%. 
Cumulative incidence curves from Cox proportional hazards models through 5 years for patients with ≥1 
DS >30% (n=447). A) primary endpoint: cardiac death, spontaneous non-TV-MI and non-TVR, B) cardiac 
death, C) non-TVR, D) spontaneous non-TV-MI. CI = confidence interval, HR = hazard ratio, non-TV-MI 
= non-target-vessel myocardial infarction, non-TVR = non-target vessel revascularization, QFR = 
Quantitative Flow Ratio. 
Figure S4. Kaplan Meier Curves of the Primary Endpoint for DS >30%. 
Displayed are time-dependent ROC (i.e. cumulative case/dynamic control) analyses at 1 year (365 days), 
2 years (730 days), 3 years (1095 days), 4 years (1460 days), and 5 years (1825 days) for QFR ≤0.80 
predicting the primary endpoint (cardiac death, spontaneous non-TV-MI, non-TVR). AUC = area under 
the curve, NPV = negative predictive value, PPV = positive predictive value, QFR = Quantitative Flow 
Ratio, ROC = receiver operating curve.  
Figure S5. Time-dependent ROC analyses. 
ROC analyses for QFR ≤0.80 vs. DS ≥50% by 3D-QCA predicting the 
primary endpoint (cardiac death, spontaneous, non-TV-MI, non-TVR) at 
5 years. AUC = area under the curve, DS% = diameter stenosis, NPV = 
negative predictive value, PPV = positive predictive value, QFR = 
Quantitative Flow Ratio, ROC = receiver operating curve. 3D-QCA = 
3D-Quantitative Coronary Angiography.  
Figure S6. ROC analyses for QFR ≤0.80 and DS ≥50%. 
QFR = Quantitative Flow Ratio, RCA = right coronary artery. 
Figure S7. Flowchart of Treated Non-Target-Vessels. 
DS% = diameter stenosis. QFR = Quantitative Flow Ratio.  
Figure S8. Distribution of DS% and QFR of Treated Non-Target-Vessels. 
 DS% = diameter stenosis, LAD = left anterior descending artery, LCX = left 
circumflex artery, QFR = Quantitative Flow Ratio, RCA = right coronary artery. 
Figure S9. Scatterplot DS% vs. QFR of Treated Non-Target-Vessels.
Non-TVR = non-target vessel revascularization, 2D-QCA = 2D-Quantitative Coronary Angiography, QFR 
= Quantitative Flow Ratio.  
Figure S10. Flowchart of Matched 2D-QCA and QFR of Vessels with a Non-TVR Event. 
